Distinct genetic alterations occur in ovarian tumor cells selected for combined resistance to carboplatin and docetaxel

ABSTRACT: Background: Current protocols for the treatment of ovarian cancer include combination chemotherapy with a platinating agent and a taxane. However, many patients experience relapse of their cancer and the development of drug resistance is not uncommon, making successful second line therapy difficult to achieve. The objective of this study was to develop a cell line resistant to both carboplatin and docetaxel (dual drug resistant ovarian cell line A2780CBNDXL), along with single agent resistant lines (docetaxel resistant A2780DXL and carboplatin resistant A2780CBN), to investigate the mechanisms which underlie the development of dual drug resistance. Methods: The A2780 epithelial ovarian cancer cell line was used to select for isogenic carboplatin, docetaxel and dual drug resistant cell lin

ORGANISM(S): Homo sapiens

SUBMITTER: baoqing guo 

PROVIDER: E-GEOD-39337 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress